| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Stomach Neoplasms | D013274 | 24 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Gastritis | D005756 | 27 associated lipids |
| Heart Failure | D006333 | 36 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hirschl AM et al. | In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. | 2000 | Antimicrob. Agents Chemother. | pmid:10858365 |
| Goswami S et al. | Anti-Helicobacter pylori potential of artemisinin and its derivatives. | 2012 | Antimicrob. Agents Chemother. | pmid:22687518 |
| Taylor DE et al. | Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. | 1997 | Antimicrob. Agents Chemother. | pmid:9420030 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Jordan MK et al. | Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. | 2000 | Antimicrob. Agents Chemother. | pmid:10898693 |
| Cho SH et al. | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. | 2007 | Antimicrob. Agents Chemother. | pmid:17210775 |
| Ji B et al. | Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. | 2007 | Antimicrob. Agents Chemother. | pmid:17664316 |
| Yasuda H et al. | Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. | 1994 | Antimicrob. Agents Chemother. | pmid:8141568 |
| Vaara M | Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. | 1993 | Antimicrob. Agents Chemother. | pmid:8383945 |
| Gustavson LE et al. | Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. | 1995 | Antimicrob. Agents Chemother. | pmid:8540719 |
| Bakker-Woudenberg IA et al. | Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. | 2005 | Antimicrob. Agents Chemother. | pmid:15917538 |
| Yasuda H et al. | Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8239580 |
| Koh WJ et al. | Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. | 2015 | Antimicrob. Agents Chemother. | pmid:25987622 |
| Riska PF et al. | Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15328134 |
| Jung R et al. | Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. | 2000 | Antimicrob. Agents Chemother. | pmid:10681358 |
| Hultén K et al. | New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. | 1996 | Antimicrob. Agents Chemother. | pmid:9124830 |
| Sassa K et al. | Therapeutic effect of clarithromycin on a transplanted tumor in rats. | 1999 | Antimicrob. Agents Chemother. | pmid:9869567 |
| Sassa K et al. | Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. | 1999 | Antimicrob. Agents Chemother. | pmid:10543765 |
| Bosnar M et al. | Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. | 2005 | Antimicrob. Agents Chemother. | pmid:15917536 |
| Hardy DJ et al. | Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. | 1990 | Antimicrob. Agents Chemother. | pmid:2143642 |
| Subramanian S et al. | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. | 2008 | Antimicrob. Agents Chemother. | pmid:18070962 |
| Moon JE et al. | Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. | 2006 | Antimicrob. Agents Chemother. | pmid:16723556 |
| Tamaoki J et al. | Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. | 1995 | Antimicrob. Agents Chemother. | pmid:7486901 |
| Burton AJ et al. | Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. | 2015 | Antimicrob. Agents Chemother. | pmid:25824218 |
| Leuthner KD et al. | Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae. | 2006 | Antimicrob. Agents Chemother. | pmid:16436754 |
| Kohyama T et al. | Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. | 1999 | Antimicrob. Agents Chemother. | pmid:10103198 |
| GarcÃa-Arata MI et al. | Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. | 1999 | Antimicrob. Agents Chemother. | pmid:9925537 |
| Vance E et al. | Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. | 1995 | Antimicrob. Agents Chemother. | pmid:7574530 |
| van Zanten SJ et al. | Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. | 2003 | Antimicrob. Agents Chemother. | pmid:12821476 |
| Gikas A et al. | In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9756789 |
| Debets-Ossenkopp YJ et al. | Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9756790 |
| Schuster S et al. | Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB. | 2016 | Antimicrob. Agents Chemother. | pmid:27161641 |
| Abduljalil K et al. | Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. | 2009 | Antimicrob. Agents Chemother. | pmid:19414584 |
| Phillips RO et al. | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. | 2014 | Antimicrob. Agents Chemother. | pmid:24323473 |
| Ménard A et al. | PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:11897613 |
| Liou JM et al. | Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. | 2011 | Antimicrob. Agents Chemother. | pmid:21189342 |
| Matic V et al. | Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. | 2004 | Antimicrob. Agents Chemother. | pmid:15504828 |
| Kosowska K et al. | Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. | 2004 | Antimicrob. Agents Chemother. | pmid:15504829 |
| Bae S et al. | Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. | 2010 | Antimicrob. Agents Chemother. | pmid:19884366 |
| Spyridaki A et al. | Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. | 2012 | Antimicrob. Agents Chemother. | pmid:22564837 |
| Ednie LM et al. | Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). | 1997 | Antimicrob. Agents Chemother. | pmid:9303406 |
| Lazard T et al. | Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. | 1993 | Antimicrob. Agents Chemother. | pmid:7684213 |
| Emori M et al. | Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. | 1993 | Antimicrob. Agents Chemother. | pmid:7684214 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Ji B et al. | Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1828136 |
| Hardy RD et al. | Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. | 2003 | Antimicrob. Agents Chemother. | pmid:12709330 |
| Tomioka H et al. | Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. | 2002 | Antimicrob. Agents Chemother. | pmid:11796367 |
| Ramón-GarcÃa S et al. | Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 | Antimicrob. Agents Chemother. | pmid:21576426 |
| Miltner EC and Bermudez LE | Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10858369 |
| Kawai Y et al. | Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. | 2013 | Antimicrob. Agents Chemother. | pmid:23459497 |
| Nakamura S et al. | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. | 2010 | Antimicrob. Agents Chemother. | pmid:19949056 |
| Mukherjee D et al. | Vancomycin and Clarithromycin Show Synergy against . | 2017 | Antimicrob. Agents Chemother. | pmid:28923867 |
| Jorgensen JH et al. | Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. | 1991 | Antimicrob. Agents Chemother. | pmid:1834012 |
| Fish DN and Abraham E | Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. | 1999 | Antimicrob. Agents Chemother. | pmid:10223952 |
| Greendyke R and Byrd TF | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. | 2008 | Antimicrob. Agents Chemother. | pmid:18378709 |
| Choi GE et al. | Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. | 2012 | Antimicrob. Agents Chemother. | pmid:22564831 |
| Jesus FP et al. | In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. | 2015 | Antimicrob. Agents Chemother. | pmid:26459895 |
| Hsu PI et al. | Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. | 2014 | Antimicrob. Agents Chemother. | pmid:25070099 |
| Secka O et al. | Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. | 2013 | Antimicrob. Agents Chemother. | pmid:23263004 |
| Ji B et al. | Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. | 1996 | Antimicrob. Agents Chemother. | pmid:8878595 |
| Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. | 1998 | Antimicrob. Agents Chemother. | pmid:9517944 |
| Fernandes PB et al. | In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. | 1986 | Antimicrob. Agents Chemother. | pmid:2949695 |
| Fattorini L et al. | Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. | 1998 | Antimicrob. Agents Chemother. | pmid:9517960 |
| Heifets L | Susceptibility testing of Mycobacterium avium complex isolates. | 1996 | Antimicrob. Agents Chemother. | pmid:8843278 |
| Alper CM et al. | Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible, -intermediate, and -resistant Streptococcus pneumoniae in the chinchilla. | 1996 | Antimicrob. Agents Chemother. | pmid:8843299 |
| Falzari K et al. | In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. | 2005 | Antimicrob. Agents Chemother. | pmid:15793125 |
| Rana KZ et al. | Clarithromycin does not affect phosphorylation of zidovudine in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8843311 |
| Segreti J et al. | In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2952061 |
| Alhajlan M et al. | Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. | 2013 | Antimicrob. Agents Chemother. | pmid:23545534 |
| Benson CA et al. | In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2952063 |
| Carr RA et al. | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. | 1998 | Antimicrob. Agents Chemother. | pmid:9593146 |
| Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
| Sörberg M et al. | Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9593154 |
| Brophy DF et al. | Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. | 2000 | Antimicrob. Agents Chemother. | pmid:10722500 |
| Matsuzaki J et al. | Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. | 2012 | Antimicrob. Agents Chemother. | pmid:22203601 |
| Rastogi N et al. | Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. | 1992 | Antimicrob. Agents Chemother. | pmid:1482157 |
| Derouin F et al. | Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1482160 |
| Ji B et al. | Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834886 |
| Yamamoto T et al. | Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834892 |
| Ji B et al. | How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? | 1996 | Antimicrob. Agents Chemother. | pmid:8834894 |
| Goldstein EJ and Citron DM | Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents. | 1993 | Antimicrob. Agents Chemother. | pmid:8390810 |
| Giamarellos-Bourboulis EJ et al. | Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. | 2004 | Antimicrob. Agents Chemother. | pmid:14693524 |
| Dattwyler RJ et al. | Clarithromycin in treatment of early Lyme disease: a pilot study. | 1996 | Antimicrob. Agents Chemother. | pmid:8834900 |
| Versalovic J et al. | Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. | 1996 | Antimicrob. Agents Chemother. | pmid:8834903 |
| Hultén K et al. | Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. | 1997 | Antimicrob. Agents Chemother. | pmid:9371366 |
| Carter G et al. | A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. | 2004 | Antimicrob. Agents Chemother. | pmid:15561879 |
| Yamazaki T et al. | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. | 2007 | Antimicrob. Agents Chemother. | pmid:17387152 |
| Wallace RJ et al. | Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. | 1996 | Antimicrob. Agents Chemother. | pmid:8807061 |
| Gillum JG et al. | Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. | 1996 | Antimicrob. Agents Chemother. | pmid:8807068 |
| Walker KJ et al. | Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. | 1994 | Antimicrob. Agents Chemother. | pmid:7811010 |
| Bogdanovich T et al. | Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. | 2006 | Antimicrob. Agents Chemother. | pmid:16495248 |
| Welsh L et al. | In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8787907 |
| Liu KY et al. | Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. | 2014 | Antimicrob. Agents Chemother. | pmid:24687504 |
| Fontana C et al. | New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. | 2002 | Antimicrob. Agents Chemother. | pmid:12435674 |
| Noreddin AM et al. | Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. | 2002 | Antimicrob. Agents Chemother. | pmid:12435719 |
| Nagaoka K et al. | Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. | 2013 | Antimicrob. Agents Chemother. | pmid:23380724 |
| Furney SK et al. | Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. | 1995 | Antimicrob. Agents Chemother. | pmid:7793895 |
| Renvoisé A et al. | Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. | 2015 | Antimicrob. Agents Chemother. | pmid:26324275 |
| Nash KA | Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). | 2003 | Antimicrob. Agents Chemother. | pmid:14506008 |
| Best LM et al. | Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. | 2003 | Antimicrob. Agents Chemother. | pmid:14506021 |